SAN DIEGO, Nov. 24 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow(R) System, the first rapid and easy-to-use diagnostic system for measuring an individual’s response to multiple antiplatelet agents (e.g. Plavix(R) and aspirin), announced today that Timothy I. Still, President and CEO of Accumetrics, and Gregory J. Tibbitts, Chief Financial Officer of Accumetrics, will be presenting a corporate overview at the 21st Annual Piper Jaffray Health Care Conference being held in New York City on December 1-2, 2009 at The Palace Hotel.
Accumetrics’ presentation will be on Tuesday, December 1, 2009 at 9:10 am eastern time. Management will also be available for one-on-one meetings with investors participating in Piper Jaffray’s Health Care Conference. For those who would like to schedule an appointment with Accumetrics’ management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at afields@lhai.com or contact your Piper Jaffray representative.
Accumetrics’ VerifyNow System is the first rapid and easy to use platform to help physicians determine an individual’s response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient(TM)) and clopidogrel (Plavix)), and GP IIb/IIIa inhibitors (e.g. ReoPro(R) and Integrilin(R)), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions. For more information about the Company and its products, visit www.accumetrics.com.
Accumetrics, Inc.
